How The World’s First Drug For Amyloid Disease Works

<p>Main Category: Alzheimers / Dementia
Also Included In: Neurology / Neuroscience;  Regulatory Affairs / Drug Approvals
Article Date: 31 May 2012 0:00 PDT</p>

<p> email to a crony   printer accessible   opinions   </p>

<p>! rate article
Patient / Public:
Healthcare Prof:</p>

<p>Scientists from The Scripps Research Institute and Pfizer Inc. have published a new investigate display how a new drug called tafamidis (Vyndaqel®) works. Tafamidis, authorized for use in Europe and now underneath examination by a US Food and Drug Administration (FDA), is a initial remedy authorized by a vital regulatory group to provide an amyloid disease, a category of conditions that embody Alzheimers.</p>

<p>Tafamidis treats a lethal haughtiness illness caused by transthyretin (TTR) amyloid fibril formation, or a accumulation of aberrant assemblies of a TTR protein. The drug inhibits TTR aggregation, and clinical trials have shown that it delays...